The current status of therapeutic HPV vaccine

Annals of Medicine

Volumn 28, Issue 6, 1996, Pages 471-477

  Van Driel, Willemien J ^a   Ressing, Maaike E ^a   Brandt, Remco M P ^a   Toes, René E M ^a   Fleuren, Gert Jan ^a   Trimbos, J Baptist ^a   Kast, W Martin ^a,b   Melief, Cees J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Carcinoma; Cervix; Cytotoxic T lymphocytes; Human papillomavirus; Immunotherapy; Vaccination

Indexed keywords

VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 0030475848     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899608999110     Document Type: Review

References (71)

1. Human Papillomaviruses. IARC Monogaphs on the evaluation of carcinogenic risks to humans, 1995; 64.
2. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990; 82: 1477-84.
3. van den Brule AJC, Walboomers JMM, du Maine M, Kenemans P, Meijer CJLM. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991; 48: 404-8.
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802.
5. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytologica 1983; 27: 220-4
6. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
7. Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone M, Creighton LE. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988; 10: 105-10.
8. Bonomi P, Blessing J, Ball H, Hanjani P, Disaia PJ. A phase II evaluation of cis-platin and 5-fluoro-uracil in patients with advanced squamous cell carcinoma of the cervix: a Gynaecologic Oncology Group study. Gynecol Oncol 1989; 34: 357-61.
9. Lawhead R, Clark D, Smith D. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10 year review of the Memorial Sloan Kettering Cancer Center Experience. Gynecol Oncol 1989; 33: 279-82.
10. Alberts DS, Kronmal R, Baker LH, et al. Phase II randomized trial of cis-platin chemotherapy regimen in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group study. J Clin Oncol 1987; 5: 1791-5.
11. Feldman M, Eisenbach L. MHC class I genes controlling the metastatic phenotype of tumor cells. Semin Cancer Biol 1991; 2: 337-46.
12. Tweddel G, Heller P, Cunnane M, Multhaupt H, Roth K. The correlation between HIV seropositivity, cervical dysplasia, and HIV subtypes 6/11, 16/18, 31/33/35. Gynecol Oncol 1994; 52: 161-4.
13. Cromme FV, Meijer CJLM, Snijders PJF, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993; 67: 1372-80.
14. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995; 69: 7791-9.
15. Villiers EM. Heterogeneity of the human papillomavirus group. J Virol 1989; 63: 4898-903.
16. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
17. Vogelstein B, Kinzler RW. P53 function and dysfunction. Cell 1992; 70: 523-6.
18. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-46.
19. Smotkin D, Wettstein FO. Transcription of HPV16 early genes in a cervical cancer and a cervical cancer derived cell line, and the identification of the E7 protein. Proc Natl Acad Sci USA 1986; 83: 4680-4.
20. Baker CJ, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of HPV16 sequences in cervical carcinoma cell lines. J Virol 1987; 61: 962-71.
21. Hilders CGJM, Houbiers JGA, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ. Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993; 69: 651-9.
22. Hilders CGJM, Houbiers JGA, Krul EJT, Fleuren GJ. The expression of histocompatibility-related leucocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994; 101: 5-12.
23. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990; 46: 1029-34.
24. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993; 14: 491-8.
25. Tomita Y, Nishiyama T, Fujiwara M, Sato S. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br J Cancer 1990; 62: 354-9.
26. van Driel WJ, Tjiong MY, Hilders CGJM, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA-expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996; 62: 33-41.
27. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-40.
28. Neefjes JJ, Momburg F, Hämmerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993; 261: 769-71.
29. Halloran PF, Autenried P, Ramassar V, Urmson J, Cockfield S. Local T cell responses induce widespread MHC expression. J Immunol 1992; 148: 3837-46.
30. Melief CJM, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv 1992; 13: 81-99.
31. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994; 74: 1275-82.
32. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1318-21.
33. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-75.
34. Kast WM, Brandt RMP, Drijfhout JW, Melief CJM. Human leucocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993; 14: 115-20.
35. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904-12.
36. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154: 5934-43.
37. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leucocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996; 56: 1-7.
38. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985; 22: 27-40.
39. Miescher S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and there supernatants on proliferative responses of lymphocytes. J Immunol 1986; 139: 1899-907.
40. Hilders CGJM, Ras L, Van Eendenburg JDH, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994; 57: 805-13.
41. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, et al. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995; 25: 2638-41.
42. Toes REM, Offringa R, Blom RJJ, et al. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 1995; 154: 3396-405.
43. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes. Cell 1989; 59: 603-14.
44. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
45. Chen L, Thomas KE, Hu SL, Hellström I, Hellström KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110-4.
46. Schiller JT, Boden RBS. Papillomavirus-like particles. Papillomavirus Rep 1995; 6: 121-8.
47. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L2 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89: 12180-4.
48. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
49. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70: 960-5.
50. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13: 1509-14.
51. Kern D, Klarnet J, Jensen M, Greenberg R Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I restricted CTL. J Immunol 1986; 136: 4303-10.
52. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P. Induction in a murine tumour of immunogenic tumour variants by transfection with a foreign gene. Cancer Res 1988; 48: 2975-80.
53. Hui KM, Sim TF, Foo TT, Oei AA. Tumor rejection mediated by transfection with allogenic class-I histocompatibility gene. J Immunol 1989; 143: 3835-41.
54. Gelber C, Plaskin D, Vadai E, Feldman M, Eisenbach L. Abolishment of metastasis formation by murine tumour cells transfected with 'foreign' H-2K genes. Cancer Res 1989; 49: 2366-72.
55. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
56. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994; 6: 722-7.
57. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
58. Liu Y, Linsley P. Costimulation of T cell growth. Curr Opin Immunol 1992; 4: 265-70.
59. Harding F, Allison J. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791-6.
60. Chen L, Ashe S, Brady W, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-102.
61. Townsend S, Allison J. Tumor rejection after direct co-stimulation of CD8+T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70.
62. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-32.
63. Aichele P, Brouscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming vs. T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261-6.
64. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1: 443-6.
65. Mueller DL, Jenkins MK. Molecular mechanisms underlying functional T-cell unresponsiveness. Curr Opin Immunol 1995; 7: 375-81.
66. Inaba K, Metlay JP, Crowley MT, Witmer-Pack M, Steinman RM. Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 1990; 6: 197-206.
67. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329: 1-9.
68. Inaba K, Romani N, Steinman RM. An antigen-independent contact mechanism as an early step in T cell-proliferative responses to dendritic cells. J Exp Med 1989; 170: 527-42.
69. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alfa cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-61.
70. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-302.
71. Ossevoort MA, Feltkamp MCW, van Veen KJH, Melief CJM, Kast WM. Dendritic cells as carriers for a cytotoxic T lymphocyte epitope based peptide vaccine in protection against a human papillomavirus type 16 induced tumor. J Immunother 1995; 18: 86-94.